Alaunos Therapeutics, Inc. (then ZIOPHARM Oncology, Inc.) — Q2 2014 Form 10-Q
The supplied filing is for ZIOPHARM Oncology, Inc., not a company named Alaunos Therapeutics, Inc. It covers the unaudited quarter and six months ended June 30, 2014; filed August 7, 2014. Unless otherwise noted, financial amounts below are in millions of dollars.
Business context and reporting period
ZIOPHARM was a development-stage biopharmaceutical company focused on cancer therapies. Its lead program was the Intrexon-partnered synthetic biology candidate Ad-RTS-IL-12 + veledimex, being studied in Phase 2 melanoma and breast cancer trials. The company had no approved products and generated only minimal collaboration revenue. It had discontinued palifosfamide development for soft tissue sarcoma after the Phase 3 PICASSO 3 trial missed its primary endpoint, and was seeking partners for certain small-molecule programs.
Financial results and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $0.2 | $0.2 | $0.4 | $0.4 |
| Research and development expense | $8.3 | $14.8 | $14.9 | $33.9 |
| General and administrative expense | $3.0 | $3.7 | $6.5 | $8.4 |
| Net loss | $5.6 | $18.7 | $15.3 | $31.5 |
| Net loss per share | $0.06 | $0.22 | $0.15 | $0.38 |
- Cash and cash equivalents were $53.0 at June 30, down from $68.2 at December 31, 2013. Cash equivalents included $51.7 in a Treasury money-market fund.
- Operating cash outflow was $16.3 for the first half, compared with $35.0 a year earlier. Investing outflow was $0.1; financing provided $1.2, mainly from employee stock-option exercises.
- Working capital was $43.2, versus $62.5 at year-end 2013. Total liabilities were $17.6; the filing reports no conventional borrowings or interest expense. The $6.1 warrant liability is a fair-value accounting liability.
- Accumulated deficit was $356.1. Management estimated available cash would fund operations into the third quarter of 2015, but said further financing would be needed for longer-term development. No committed additional funding source was identified.
- Contractual obligations totaled $6.3: $3.8 operating leases, $2.1 royalty and license fees, and $0.4 contract milestones/installments.
Material changes versus the prior comparable period
- First-half R&D expense fell 56% and G&A fell 23%, largely reflecting the 2013 restructuring and reduced spending after termination or suspension of palifosfamide trials. Increased synthetic-biology discovery and nonclinical work partly offset the R&D reductions.
- First-half net loss improved by $16.2, while operating cash use declined by $18.7. Revenue remained unchanged at $0.4 for the half-year.
- A $5.7 first-half gain from the change in fair value of warrant liabilities reduced reported net loss; this was a noncash valuation item. The prior-year period included a $10.4 gain from the same item.
Outlook, commentary, risks, and unusual items
- Management prioritized brain cancer, followed by breast cancer and melanoma, and expected additional Phase 2 data in Q4 2014. It planned a Phase 1 brain-cancer study in the second half of 2014, subject to FDA discussions, and anticipated multiple IND filings through 2015.
- On July 31, 2014, after quarter-end, ZIOPHARM amended and restated its Solasia agreement, granting Solasia an exclusive worldwide license for darinaparsin. Solasia would bear development, manufacturing, and commercialization costs; ZIOPHARM could receive milestones, royalties, and sublicense revenue. The filing reclassified the remaining $2.3 of Solasia deferred revenue as current because ZIOPHARM was no longer required to perform the related research and development effort.
- Intrexon, whose CEO and largest stockholder was also a ZIOPHARM director, was a related party. ZIOPHARM expensed $5.6 for Intrexon services in the first half, including $2.2 accrued at June 30. Under the channel agreement, Intrexon is entitled to 50% of net profits or certain sublicense revenue, subject to the agreement’s terms.
- Key risks include the need for additional capital, uncertain clinical and regulatory outcomes, rising costs of synthetic-biology development, reliance on Intrexon and third-party manufacturers and clinical organizations, and potential dilution or program delays if financing is unavailable. Management cautioned that actual cash needs could exceed its estimates.
- The company reported no material legal proceedings as of June 30 and stated that disclosure controls were effective. The filing also identified upcoming warrant expirations in September and December 2014; proceeds would arise only if warrants were exercised.
Important facts for investors to verify
- Confirm the issuer and period: the provided 10-Q names ZIOPHARM Oncology, Inc. and covers Q2 2014, despite the request metadata naming Alaunos Therapeutics, Inc.
- Review the July 31 Solasia amendment, including the final milestone, royalty, sublicense, and licensor-sharing terms.
- Assess the assumptions underlying management’s cash runway estimate through Q3 2015 and the financing required thereafter.
- Track clinical-trial progress, safety findings, regulatory discussions, and timing for the planned brain-cancer study and expected melanoma and breast-cancer data.
- Distinguish operating performance from the noncash warrant remeasurement gain, and assess related-party spending and the potential impact of warrant exercises or expirations.